| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | VNLG/124 | GDSC1000 | pan-cancer | AAC | 0.42 | 3e-40 |
| mRNA | linifanib | GDSC1000 | pan-cancer | AAC | 0.39 | 7e-30 |
| mRNA | AC220 | GDSC1000 | pan-cancer | AAC | 0.37 | 2e-27 |
| mRNA | BRD-A71883111 | CTRPv2 | pan-cancer | AAC | 0.34 | 4e-21 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.4 | 3e-19 |
| mRNA | ATRA | CTRPv2 | pan-cancer | AAC | 0.27 | 3e-15 |
| mRNA | (5Z)-7-Oxozeaenol | GDSC1000 | pan-cancer | AAC | 0.22 | 1e-12 |
| mRNA | RDEA119 | GDSC1000 | pan-cancer | AAC | 0.22 | 1e-12 |
| mRNA | AZD6244 | CCLE | pan-cancer | AAC | 0.3 | 4e-12 |
| mRNA | tretinoin:carboplatin (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.23 | 5e-12 |